We are live on ! Find out more

1,043 hedge funds and large institutions have $20.7B invested in GSK in 2026 Q1 according to their latest regulatory filings, with 125 funds opening new positions, 315 increasing their positions, 380 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $222M | Put options by funds: $137M

51% more first-time investments, than exits

New positions opened: 125 | Existing positions closed: 83

36% more funds holding in top 10

Funds holding in top 10: 11 → 15 (+4)

4% more funds holding

Funds holding: 1,005 → 1,043 (+38)

1% less ownership

Funds ownership: 19.72% → 18.71% (-1%)

17% less repeat investments, than reductions

Existing positions increased: 315 | Existing positions reduced: 380

41% less capital inflows, than outflows

Capital inflows: $1.65B | Capital outflows: $2.79B

Holders
1,043
Holders Change
+38
Holders Change %
+3.78%
% of All Funds
12.66%
Holding in Top 10
15
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+36.36%
% of All Funds
0.18%
New
125
Increased
315
Reduced
380
Closed
83
Calls
$222​M
Puts
$137​M
Net Calls
+$85.7​M
Net Calls Change
-⁠$49.4​M

GSK Hedge Fund Activity: Q1 2026 in Review

1,043 of the 8,241 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2026, worth a combined $20.7B — up 5.9% from $19.5B a quarter earlier.

Buyers outnumbered sellers: 125 funds opened new GSK positions and 83 closed out — a net gain of 42 holders — while 315 added to existing stakes and 380 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $282M. The largest seller was Dodge & Cox, cutting an estimated $534M.

  • 1,043 institutional investors held GSK (GSK) as of Q1 2026, up from 1,005 in Q4 2025.
  • Funds reported $20.7B of GSK stock for Q1 2026, up 5.9% quarter-over-quarter.
  • 125 funds opened new GSK positions in Q1 2026 and 83 closed out, a net change of +42 holders.
  • The largest GSK buyer in Q1 2026 was Morgan Stanley, an estimated $282M added.
  • The largest GSK seller in Q1 2026 was Dodge & Cox, an estimated $534M sold.

Based on aggregated 13F filings for Q1 2026.